Evidence review · Drug selection
Ozempic vs Mounjaro for type 2 diabetes: which controls blood sugar better?
The honest verdict
For raw glycemic control plus weight loss, tirzepatide (Mounjaro) has the strongest data — the SURPASS program showed the largest HbA1c reductions in the class. Semaglutide (Ozempic) is the pick when cardiovascular or kidney outcomes drive the decision, backed by SUSTAIN-6 and the FLOW kidney trial.
The options, side-by-side
| Drug | Trial evidence | Fit note |
|---|---|---|
| Tirzepatide (Mounjaro) | SURPASS: largest HbA1c drop in class | Best for maximum glycemic + weight effect |
| Semaglutide (Ozempic) | SUSTAIN-6 CV benefit + FLOW kidney benefit | Best when CV or kidney outcomes drive the choice |
| Dulaglutide (Trulicity) | REWIND: CV benefit | Established CV evidence, lower weight effect than the above |
| Oral semaglutide (Rybelsus) | PIONEER program | For patients who will not inject; strict empty-stomach dosing rules |
Drug selection is a prescriber decision. This table summarizes the trial evidence — it is not a prescription or a substitute for clinical judgment.
Glycemic control: tirzepatide leads the class
The SURPASS trial program established tirzepatide as the most potent glucose-lowering agent in the incretin class, with HbA1c reductions reaching roughly 2.0-2.4 percentage points at higher doses — larger than semaglutide, dulaglutide, or basal insulin comparators in head-to-head arms.
That potency comes with the largest weight effect too, which matters because weight loss independently improves insulin sensitivity in type 2 diabetes. For a patient whose primary problem is inadequate glycemic control plus excess weight, tirzepatide is the evidence-backed first choice absent a contraindication or coverage barrier.
- Jastreboff AM et al. — Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — New England Journal of Medicine, 387:205-216, 2022
Cardiovascular and kidney outcomes: semaglutide’s edge
Glycemic numbers are not the only endpoint that matters in type 2 diabetes. SUSTAIN-6 demonstrated cardiovascular risk reduction with semaglutide in patients with type 2 diabetes at high cardiovascular risk, and the FLOW trial showed semaglutide slowed the progression of chronic kidney disease in this population — a major outcome given how often diabetic kidney disease drives long-term morbidity.
ADA 2024 Standards of Care recommend a GLP-1 with proven cardiovascular benefit for patients with type 2 diabetes and established atherosclerotic cardiovascular disease, independent of HbA1c target. If you have diabetic kidney disease or established cardiovascular disease, that guidance points toward semaglutide (or dulaglutide, which has REWIND) over choosing purely on HbA1c potency.
- ADA — Standards of Care in Diabetes 2024 — American Diabetes Association
Hypoglycemia and adjusting your other diabetes medications
GLP-1s stimulate insulin release only when glucose is elevated, so on their own they rarely cause hypoglycemia. Risk appears in combination: adding a GLP-1 to insulin or a sulfonylurea (glipizide, glimepiride) can push glucose too low, so prescribers typically reduce those doses at initiation.
Metformin is commonly continued alongside a GLP-1 with no dose change. SGLT2 inhibitors also combine well and add their own kidney and heart-failure benefits. The regimen should be built deliberately — know the symptoms of a low (shakiness, sweating, confusion) and how to treat one if you take insulin or a sulfonylurea.
Coverage is easier with a diabetes diagnosis
This is the practical advantage diabetic patients have: the diabetes indication is broadly covered on commercial and Medicare formularies, whereas the obesity indication (Wegovy, Zepbound) is frequently excluded. Ozempic and Mounjaro are therefore usually far easier and cheaper to get approved than their obesity-labeled twins.
Prior authorization is still common and typically asks for HbA1c documentation and a metformin trial. If you are denied, the appeal path is the same as any GLP-1 denial — see our cost-lowering menu and prior-auth letter tool.
How to talk to your prescriber
Bring your recent HbA1c trend, your current diabetes regimen (especially any insulin or sulfonylurea), and your kidney function labs (eGFR, urine albumin-creatinine ratio). Also flag any history of heart attack, stroke, or heart failure — it may change the drug choice under ADA guidance.
Useful questions: "Given my HbA1c and my kidney numbers, do you lean tirzepatide or semaglutide?" "Do we need to lower my insulin or sulfonylurea dose?" "Does my cardiovascular history change the choice?" "What HbA1c are we targeting?"
Frequently asked
Which GLP-1 is best for type 2 diabetes?
For maximum HbA1c and weight reduction, tirzepatide (Mounjaro) has the strongest data from the SURPASS program. For patients with established cardiovascular disease or diabetic kidney disease, semaglutide (Ozempic) has the deeper outcomes evidence (SUSTAIN-6, FLOW). Both are reasonable — the tiebreaker is usually your comorbidities and coverage.
Is Ozempic or Mounjaro better for lowering A1c?
Mounjaro (tirzepatide) produced larger HbA1c reductions in trials — roughly 2.0-2.4 percentage points at higher doses versus about 1.5-1.8 for semaglutide. Both are highly effective; tirzepatide is more potent on this specific endpoint.
Can I take a GLP-1 with insulin?
Yes, and the combination is common. The important adjustment is that your insulin dose usually needs to be reduced when starting a GLP-1 to avoid hypoglycemia, since the two effects stack. This is a prescriber-managed change — do not adjust insulin on your own.
Will insurance cover a GLP-1 if I have type 2 diabetes?
Usually much more readily than for weight loss alone. The diabetes indication (Ozempic, Mounjaro, Trulicity) is broadly covered on commercial and Medicare formularies. Prior authorization is still common and typically requires HbA1c documentation and often a metformin trial.
Next steps
Other situations
Your situation may span more than one of these. Each guide reads the trial evidence for a different starting point.
For women
The best GLP-1 for women: what the trial evidence actually supports
For men
The best GLP-1 for men: what the trial evidence actually supports
For adults over 50
The best GLP-1 for adults over 50: what the evidence supports
For women with PCOS
Ozempic for PCOS: what the evidence actually supports
For people with insulin resistance or prediabetes
The best GLP-1 for insulin resistance and prediabetes
For people with obstructive sleep apnea
Zepbound for sleep apnea: what SURMOUNT-OSA actually showed
For people who have had bariatric surgery
The best GLP-1 after bariatric surgery: managing weight regain
For people with a BMI of 40 or higher
The best GLP-1 for BMI 40+: severe obesity and the surgery question
Sources
- Jastreboff AM et al. — Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — New England Journal of Medicine, 387:205-216, 2022
- Wilding JPH et al. — Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1) — New England Journal of Medicine, 384:989-1002, 2021
- ADA — Standards of Care in Diabetes 2024 — American Diabetes Association
- Wegovy (semaglutide 2.4 mg) FDA prescribing information, 2024 revision — US FDA
This page describes published evidence and is not medical advice. GLP-1 drug selection is a decision for a licensed prescriber who has assessed you individually.